Myeloid cell surface antigen CD33 — Drug Target

All drugs that target Myeloid cell surface antigen CD33 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

CD33-directed Immunoconjugate [EPC]

Marketed (2)

• Mylotarg · Wyeth Pharms Inc · CD33-directed Immunoconjugate [EPC] · Oncology
  Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them.
• Mylotarg · Pfizer · CD33-directed Immunoconjugate [EPC] · Oncology
  Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells.